Syndax Pharmaceuticals’ Earnings Call Highlights Growth Push

Syndax Pharmaceuticals Inc. ((SNDX)) has held its Q4 earnings call. Read on for the main highlights of the call.

Syndax Pharmaceuticals’ latest earnings call struck a notably upbeat tone, spotlighting rapid commercial uptake, accelerating revenues, and a strong cash cushion, even as management acknowledged high near‑term spending and execution risks. Investors heard a story of two successful oncology launches powering growth, backed by encouraging real‑world outcomes and a pipeline rich with upcoming catalysts.

Multiple Approvals and Successful Launches

Syndax has turned itself into a commercial oncology player at speed, notching three U.S. approvals in roughly a year and launching two first‑ and best‑in‑class medicines in 2025. Management framed this as proof that its R&D engine and commercial infrastructure can both deliver, setting the stage for durable growth if clinical momentum continues.

Revuforj: Robust Revenue and Quarterly Acceleration

Revuforj was the primary growth engine in 2025, generating $124.8 million in net revenue for the year. In the fourth quarter alone, revenue reached $44.2 million, up 38% quarter over quarter, with total prescriptions up about 35% and new patient starts rising roughly 20%.

Revuforj Market Penetration and NPM1 Expansion

Commercially, Revuforj has reached approximately 1,050 patients since launch, already approaching about 50% penetration of the KMT2A incident population in its first year. The recent NPM1 label expansion effectively triples the eligible annual patient pool to roughly 6,500, and with around 97% formulary coverage, NPM1 patients already accounted for about 30% of new starts in the fourth quarter.

Niktimvo: Strong Launch Performance and Contribution

Niktimvo added another leg to the growth story, posting $56 million in fourth‑quarter net revenue, up 22% sequentially, and about $151.6 million in net sales over its first 11 months on the market. Syndax recognized $42.4 million of collaboration revenue from the product in 2025, with roughly 13,500 infusions given to more than 1,400 patients and persistency running around 60%–70% at month 10.

Company Financials and Cash Position

Total Syndax revenue in 2025 reached $172.4 million, reflecting the early but rapidly scaling contributions from Revuforj and Niktimvo. The company ended the year with $394 million in cash, cash equivalents, and marketable securities, and management stated it expects to reach profitability without tapping additional capital.

Pipeline Advancement and Clinical Catalysts

Beyond commercial execution, the pipeline is moving steadily, with enrollment underway in pivotal frontline trials for revumenib, including EVOLVE‑2, REVEAL, and RAVEN. The MAXPIRe trial of axatilimab in idiopathic pulmonary fibrosis has fully enrolled about 135 patients, with top‑line data anticipated in the fourth quarter of 2026, while late‑stage chronic GVHD combination programs are slated to read out between 2027 and 2028.

Real‑World Evidence and Investigator Data

Management highlighted real‑world results that support Revuforj’s clinical profile, including data from Moffitt showing overall response rates around 77% and MRD negativity of roughly 75% in relapsed or refractory patients mainly on combination regimens. Additional investigator‑led maintenance and post‑transplant studies at MD Anderson and City of Hope were described as demonstrating favorable tolerability and promising patient outcomes.

Expense Guidance and Spending Stability

On the cost side, Syndax guided 2026 R&D and SG&A expenses to about $400 million, excluding roughly $50 million in noncash stock‑based compensation. Management emphasized that spending should remain relatively flat quarter to quarter, signaling a deliberate but stable investment pace in both commercialization and clinical development.

High Operating Expenses Versus Current Revenue

That spending level stands in sharp contrast to the company’s 2025 revenue of $172.4 million, underscoring a sizable gap that must be closed by continued sales growth. The implied near‑term cash burn reflects a conscious choice to invest heavily ahead of, or alongside, the expected ramp in product revenues.

Profitability and Cash Runway Sensitivity

While executives reiterated their confidence in achieving profitability without raising new funds, the combination of a roughly $400 million expense run‑rate and $394 million in year‑end cash leaves limited room for error. Any delays in demand expansion, pricing pressure, or clinical setbacks could tighten the runway and force management to reconsider its capital plan.

Revuforj Treatment Duration and Revenue Sensitivity

One key lever is extending treatment duration for Revuforj, which averaged just 4–6 months in 2025 and capped revenue per patient. The company expects average duration to lengthen to 6–12 months in year two, but the financial model is sensitive to whether these longer courses materialize at the pace and magnitude management projects.

Partial Post‑Transplant Maintenance Uptake

Another opportunity lies in post‑transplant maintenance, where only about 40%–45% of KMT2A patients restarted Revuforj therapy by the fourth quarter, up from about 35%–40% previously. Management has referenced the potential for 70%–80% long‑term uptake, but reaching that level will require continued physician education, data generation, and competitive differentiation.

Pending Clinical and Regulatory Readouts

The next phase of value creation hinges on forthcoming data, particularly from frontline pivotal trials for revumenib and the MAXPIRe IPF study expected to read out in late 2026. Management acknowledged that negative or inconclusive results from these programs would meaningfully temper growth expectations and could weigh on the company’s valuation.

Competitive and Market Share Dynamics

Competition is already emerging, with another menin inhibitor on the market, and Syndax is currently seeing minimal share impact but remains cautious about longer‑term dynamics. Future market share in NPM1 and other segments will depend on maintaining clear clinical differentiation, expanding the evidence base, and executing effectively in a crowded hematology landscape.

Guidance and Forward‑Looking Outlook

For 2026, Syndax is guiding to continued top‑line momentum driven by Revuforj’s growing penetration, NPM1 expansion, and Niktimvo’s broader adoption in later‑line chronic GVHD. With treatment duration expected to lengthen, post‑transplant usage poised to improve, collaboration margins on Niktimvo seen rising as volumes scale, and expenses projected at about $400 million, management is signaling confidence in a path to profitability without new financing.

Syndax’s earnings call painted the picture of a company in aggressive build‑out mode, pairing rapid commercial uptake with a full clinical calendar and a sizable investment budget. For investors, the upside case rests on sustained revenue acceleration, longer Revuforj treatment durations, and positive readouts from key trials, while the main risks center on execution, competition, and a narrow cushion between spending and available cash.